
|Videos|June 30, 2017
Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Advertisement
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses 7-year follow-up data of the APT trial, which studied adjuvant paclitaxel/trastuzumab (TH) in early-stage patients with node-negative, HER2-positive breast cancer.
Tolaney presented the study results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Exploring The Application of Artificial Intelligence in Radiology Scans
2
Adjuvant Chemo Noninferor at 3 Months Vs 6 Months in Stage II/III CRC
3
Indirect Comparison Supports Zanubrutinib Monotherapy in CLL/SLL Care
4
Navigating the Surgical Nuances of Inflammatory Breast Cancer and Phyllodes Tumors
5



































